Lifeboat Foundation

Friday morning at 5:24 am (0924 GMT), a rocket owned by the US company SpaceX will blast off from Florida carrying two and a half tons of gear from NASA, only to dock three days later and 250 miles (400 kilometers) above Earth at the International Space Station.

The rocket itself is not new. It launched a NASA satellite into orbit two months ago, then landed back on Earth—upright—on a barge in the Atlantic Ocean off Cape Canaveral.

Even the Dragon capsule, carrying the cargo and affixed to the top of the rocket was used before, having flown a mission to the ISS in 2016.

After nearly four years of traveling through space, the Hayabusa2 spacecraft has successfully rendezvoused with the Ryugu asteroid, the Japan Aerospace Exploration Agency confirmed Wednesday. Let the next stage of this historic sampling-and-return mission begin!

Earlier today, mission controllers at JAXA triggered Hayabusa2’s chemical propulsion thrusters, bringing the spacecraft into orbit around Ryugu, an asteroid that’s just shy of one kilometer (0.6 miles) wide. Confirmation of the rendezvous was made at 9:35 am Japan Standard Time (JST). JAXA says Hayabusa2’s thrusters worked normally, and that the spacecraft is maintaining a constant distance from Ryugu.

Researchers have made a shocking discovery under the Pine Island Glacier in Antarctica — an active volcanic heat source, which they say has played a “critical role” in the movement and melting of the glacier.

The scientists were looking at the role the ocean plays in causing glaciers to weaken when the discovery was made.

“We were looking to better understand the role of the ocean in melting the ice shelf,” Assistant Professor Brice Loose of Newport, R.I., a chemical oceanographer and lead author of the paper, said in a statement.

Continue reading “Antarctica’s big secret: Active volcanic heat found under Pine Island Glacier” »

The Mars-Home for Mission Specialists for next few months.Team includes India born Shawna Pandya

Representatives of Congress and the National Space Council joined President Donald J. Trump, Apollo astronaut Jack Schmitt and current NASA astronaut Peggy Whitson Monday, Dec. 11, 2017, for the president’s signing of Space Policy Directive 1, a change in national space policy that provides for a U.S.-led, integrated program with private sector partners for a human return to the Moon, followed by missions to Mars and beyond.

Lunar Sample 70215 was retrieved from the Moon’s surface and returned by NASA’s Apollo 17 crew. The sample is a basaltic lava rock similar to lava found in Hawaii. It crystallized 3.84 billion years ago when lava flowed from the Camelot Crater. Sliced off a parent rock that originally weighed 8,110 grams, the sample weighs 14 grams, and is very fine grained, dense and tough.

Continue reading “Will US Make it to Mars as President Trump Signs New Directive for NASA and Mission Gets Ready” »

So what’s the catch?

For one, iPSCs can take months to make and the process is expensive. Furthermore, reverting cells back to a stem cell state wipes out their history, which is sometimes useful for studying disease progression.

In essence, iPSCs are the middlemen between one cell type and another. What if we could simply take out the middleman altogether?

Continue reading “Transdifferentiation Can Create An Endless Supply of Brain Cells—And Fast” »

Scientists at Hollings Cancer Center at the Medical University of South Carolina have found that human lung cancer cells resist dying by controlling parts of the aging process, in results published online May 10th in the Journal of Biological Chemistry. The discovery could help us better understand aging and eventually could lead to new treatments for cancer.

Cancer becomes more common as people get older, but scientists are still searching for answers about why this happens. At Hollings Cancer Center, research into the connections between aging and cancer is led by Besim Ogretmen, Ph.D., SmartState Endowed Chair in Lipidomics and Drug Discovery. Ogretmen’s team found that cancer cells have specific ways to resist dying the way normal cells do. They do so by protecting the tips of their chromosomes, which hold our DNA, from age-related damage.

Ogretmen studies how cancer cells are different than normal cells to understand how cancer grows and spreads in the body. His work is part of an $8.9 million program project grant to research how alterations of lipid metabolism affect cancer therapy. The grant is helping fund a clinical trial of an anticancer medicine to inhibit cellular signaling that helps cancer survive. The drug was found to be useful against cancer in the research reported in the group’s new paper.

In the longer term, our descendants may face even more existential decisions (provided the machines allow them to make them). How might they organise society in a world in which few people can do anything that is obviously economically productive? The world might become techno-feudal, with an owning elite hiring great numbers of cheap human servants not for their value, but for the pleasure of domination. People might instead share the abundance more equally, with all enjoying the civilised leisure that was once the province of the very few. Ours is the first civilisation to view work as the highest calling. Maybe that strange prejudice will need to be discarded.

How do you organise a society in which few people do anything economically productive?

Sorry, T-Rex — blame Nemesis.

Most if not all stars in the universe might also have a twin.

“I am extremely excited about the research involved in the current Scientific Reports article,” said Joseph I. Shapiro, M.D., senior author and dean of the Joan C. Edwards School of Medicine. “I believe that our team has not only implicated the NAKL discovered by our colleague, Dr. Zijian Xie, in the aging process but identified a novel therapeutic target as well as a specific pharmacological strategy to actually slow the aging process. Although it will be some time before we can test these concepts in human subjects, I am cautiously optimistic that clinical therapeutics will ultimately result.”

The team’s extensive year-long study first focused on aging mice who were given a western diet to stimulate oxidant stress to antagonize the NAKL. The western diet increased the functional and structural evidence for aging; however, the introduction of pNaKtide slowed these changes in the mice. The same results were then replicated when human dermal fibroblasts were exposed to different types of oxidant stress in vitro by stimulating the NAKL, increasing expression of senescence markers, and causing cell injury. With pNaKtide treatment, the researchers demonstrated that the negative attributes associated with aging were significantly dampened.

“Our data clearly suggest that the Na/K-ATPase oxidant amplification loop is intimately involved in the aging process and, if confirmed in human studies, might ultimately serve as a therapeutic target,” said first author Komal Sodhi, M.D., an associate professor of surgery and biomedical sciences at the Joan C. Edwards School of Medicine. “If the pNaKtide can be safely used in humans, it might be possible to study the applicability of that specific agent to the problem of clinical aging.”